Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry And Advocacy Groups Outline How To Restart Elective Surgeries In Midst Of COVID-19

Executive Summary

A joint guidance from medtech, nurse and hospital advocacy groups outline recommendations for how medical device representatives can get back into hospitals to help with elective surgeries after hospitals begin shifting away from mostly treating COVID-19 patients.

You may also be interested in...



CMS Chief Advises Separate Non-COVID-19 Wards At Hospitals To Allow Device-Related Elective Surgeries To Resume

To get on with the business of providing non-coronavirus procedures – including elective surgeries involving replacement joints and other non-emergency care – at US health care facilities, Medicare agency chief Seema Verma is advising hospitals and outpatient facilities to establish non-COVID-19 care (NCC) zones.

Plan To ‘Reopen’ America Gradually Allows Return Of Elective Orthopedic, Colon, Eye Surgeries

Under guidelines recently unveiled by President Trump, US health care facilities could gradually start phasing-in more elective surgeries, including commonly performed operations that were postponed due the COVID-19 outbreak – many of which involve extensive device use. Elective surgeries include orthopedic joint replacement procedures, colonoscopies and cataract-correcting procedures that could resume as early as May under Trump’s plan.

US FDA Adds 14 New Regulatory Tools To Help It Review Medical Devices

The tools include new laboratory methods, and computational models and simulations give the agency more capabilities to test and validate data in premarket submissions.

Topics

UsernamePublicRestriction

Register

OM011382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel